as 05-30-2025 4:00pm EST
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Founded: | 1974 | Country: | United States |
Employees: | N/A | City: | CLEVELAND |
Market Cap: | 256.9M | IPO Year: | 1980 |
Target Price: | $17.80 | AVG Volume (30 days): | 1.7M |
Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.95 | EPS Growth: | N/A |
52 Week Low/High: | $3.93 - $7.32 | Next Earning Date: | 05-15-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 383.07% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Alvino Mark | ABEO | Director | May 27 '25 | Sell | $6.38 | 2,000 | $12,760.00 | 90,435 | |
Alvino Mark | ABEO | Director | May 16 '25 | Sell | $5.68 | 8,000 | $45,440.00 | 90,435 | |
Seshadri Vishwas | ABEO | Chief Executive Officer | Mar 31 '25 | Sell | $4.78 | 25,000 | $119,500.00 | 1,355,322 |
ABEO Breaking Stock News: Dive into ABEO Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Zacks Small Cap Research
12 days ago
Associated Press Finance
17 days ago
GlobeNewswire
17 days ago
GlobeNewswire
18 days ago
GlobeNewswire
18 days ago
GlobeNewswire
18 days ago
Pharmaceutical Technology
19 days ago
The information presented on this page, "ABEO Abeona Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.